Obesity behaves like a chronic condition, and the trial data on stopping GLP-1 medications show why. What long-term management looks like, what a licensed provider monitors, and how to think about maintenance.
The hardest part of weight management has never been losing weight. It is keeping it off. Decades of research on diets, and now several years of data on GLP-1 medications, point to the same conclusion: body weight is regulated by a biological system that pushes back, and durable results require ongoing attention rather than a short course of treatment. This article explains what the evidence shows about stopping treatment, what long-term care typically involves, and why a licensed provider's oversight is more than a formality. It is educational and does not determine whether any treatment is right for you.
Major medical organizations, including the American Medical Association and the World Obesity Federation, classify obesity as a chronic, relapsing disease. That framing is not about labels; it reflects physiology. In a 2018 review for Medical Clinics of North America, NIH researchers Kevin Hall and Scott Kahan described the near-universal pattern of obesity interventions: early weight loss, a plateau, then gradual regain. The drivers are biological (increased appetite and reduced energy expenditure after weight loss), behavioral (adherence fades) and environmental (food is abundant and movement is optional). Their conclusion was that treating obesity "requires ongoing clinical attention," much like blood pressure or diabetes.
The medications have made this point unusually clear, because two trials specifically studied withdrawal.
STEP 1 extension (semaglutide). After 68 weeks of semaglutide 2.4 mg, during which participants lost an average of 17.3 percent of body weight, both the medication and the lifestyle program were stopped. One year later, participants had regained an average of 11.6 percentage points, about two-thirds of what they had lost. Improvements in blood pressure, lipids and blood sugar also drifted back toward baseline. The authors wrote that the findings "confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health."
SURMOUNT-4 (tirzepatide). After 36 weeks of tirzepatide, during which participants lost an average of 20.9 percent, they were randomized to continue or switch to placebo for another 52 weeks. Those who continued lost a further 5.5 percent on average. Those switched to placebo regained 14 percent. Nearly 90 percent of those who continued kept at least 80 percent of their initial loss, compared with under 17 percent of those on placebo.
These are averages, and the trials stopped treatment abruptly rather than tapering, so they may overstate what happens with a gradual, supervised transition. But the direction is unambiguous. Starting a GLP-1 medication is better understood as a decision about long-term management, not a six-month project.
Provider-guided care is not just a prescription refill. The prescribing information for the approved medications and the clinical literature describe several ongoing responsibilities:
Monitoring for safety. The labels advise watching for pancreatitis, gallbladder disease, kidney function changes after gastrointestinal illness, and, in people with diabetes, retinopathy and hypoglycemia. Periodic check-ins are how these get caught early.
Adjusting treatment to tolerance and response. Dose escalation schedules exist for a reason, and the labels specifically allow delaying increases when side effects are significant. These decisions belong to the prescriber. The FDA has reported serious adverse events linked to patients adjusting or miscalculating their own doses, particularly with compounded products drawn from vials.
Reassessing the plan over time. Some people reach a plateau and choose to maintain; some discuss adjusting dose; some consider whether a different medication is appropriate; some eventually explore stepping down under supervision. Each of these is a clinical conversation informed by your response, your side effects and your health markers.
Coordinating the non-drug side. The Lundgren trial in the New England Journal of Medicine showed that combining a GLP-1 medication with a structured exercise program produced greater weight loss and better body composition than medication alone during the maintenance year. Protein intake, resistance training, sleep and alcohol all affect outcomes, and a provider or dietitian can help set realistic targets.
Tracking what matters beyond the scale. Blood pressure, lipids, blood sugar or A1c, liver enzymes, waist circumference and functional measures tell you whether the health goals behind the weight goal are being met.
Where the medication comes from is part of ongoing care, not separate from it. Wegovy and Zepbound are FDA-approved products made by their manufacturers. Compounded semaglutide and tirzepatide, including those available through NewDay Wellness, are prepared by pharmacies and are not FDA-approved. The FDA declared the national shortages of tirzepatide (December 2024) and semaglutide (February 2025) resolved, which narrowed the legal basis for compounding copies of the approved products, and the agency has published ongoing concerns about dosing errors, storage and product quality in the compounded market.
A licensed provider who prescribes a compounded product should be able to tell you which licensed US pharmacy prepares it, how it is shipped and stored, and how doses are measured. Buying GLP-1 products from sources that do not require a prescription or a provider visit removes every one of those safeguards.
The Hall and Kahan review emphasizes that maintenance requires "weight maintenance-specific counseling," which differs from weight loss counseling. The skills are different: eating at a new, lower energy requirement indefinitely; keeping activity and strength training routine rather than goal-driven; recognizing early regain (a few kilograms) and responding before it compounds; and managing the psychological shift from active progress to steady state.
Some people maintain on a stable medication dose long-term, which is how the approved products are intended to be used. Others, with a provider, explore a supervised reduction. There is limited published evidence on tapering strategies, so this is an area where honest uncertainty should be acknowledged rather than filled with promises.
In withdrawal trials, most people regained a large share of the weight they lost, and improvements in blood pressure, lipids and blood sugar drifted back toward baseline. Those trials stopped abruptly, so a gradual, supervised transition may differ, but the direction is clear.
Not necessarily, but the approved products are intended for long-term use. Some people maintain on a stable dose; others explore a supervised reduction with a provider. Published evidence on tapering strategies is limited.
The labels advise watching for pancreatitis, gallbladder disease and kidney function changes after gastrointestinal illness, plus retinopathy and hypoglycemia in people with diabetes. Blood pressure, lipids, A1c, liver enzymes and waist circumference show whether health goals are being met.
Wegovy and Zepbound are FDA-approved. Compounded versions are not, and the FDA has published concerns about dosing errors, storage and quality. A prescribing provider should be able to tell you which licensed US pharmacy prepares your medication and how doses are measured.
Long-term weight management works well as a partnership with a licensed provider who knows your history and can adjust the plan as your body and circumstances change. This article is educational, does not promise any particular result, and does not determine whether any treatment is appropriate for you.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
GLP-1 medications copy a hormone your gut already makes. Here is what that hormone does, how the medications change appetite and digestion, and which products are FDA-approved versus compounded.
Read articleResistance training is the single most effective way to protect muscle and bone while losing weight. Here is what the guidelines recommend, what the research shows, and how to begin safely without a gym background.
Read articleGLP-1 results vary widely. In trials, most people reached at least 5 percent weight loss while a minority did not. Medication and dose, type 2 diabetes, staying on treatment and early response all help explain the spread.
Read article